Longeveron Announces Additional Positive Clinical Data and I

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B? in the Treatment of Mild Alzheimer?S Disease

Longeveron Inc. announced additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B? for the treatment of mild Alzheimer?s disease. The...

Related Keywords

, Longeveron Inc , Diffusion Tensor Imaging , Markets ,